[EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
申请人:MERCK PATENT GMBH
公开号:WO2016081679A1
公开(公告)日:2016-05-26
The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, useful as IRAK inhibitors.
本发明涉及式I化合物或其药用可接受盐,用作IRAK抑制剂。
Solid acid-catalyzed conversion of furfuryl alcohol to alkyl tetrahydrofurfuryl ether
作者:Quan Cao、Jing Guan、Gongming Peng、Tonggang Hou、Jianwei Zhou、Xindong Mu
DOI:10.1016/j.catcom.2014.08.030
日期:2015.1
acidic zeolite HZSM-5 (Si/Al = 25) achieved 58.9% selectivity of methyl furfuryl ether (MFE) and 44.8% selectivity of ethyl furfuryl ether (EFE) from etherification of furfurylalcohol with methanol and ethanol. MFE and EFE were quantitatively hydrogenated into methyl tetrahydrofurfuryl ether (MTE) and ethyl tetrahydrofurfuryl ether (ETE) using a Raney Ni catalyst.
酸性沸石HZSM-5(Si / Al = 25)通过糠醇与甲醇和乙醇的醚化反应实现了甲基糠基醚(MFE)的58.9%选择性和乙基糠基醚(EFE)的44.8%选择性。使用阮内镍催化剂将MFE和EFE定量氢化为甲基四氢糠基醚(MTE)和乙基四氢糠基醚(ETE)。
Simultaneous hydrogenation and acid-catalyzed conversion of the biomass-derived furans in solvents with distinct polarities
作者:Xun Hu、Sri Kadarwati、Yao Song、Chun-Zhu Li
DOI:10.1039/c5ra22414d
日期:——
dominant reaction pathway. On the contrary, with ethanol as the solvent, the full hydrogenation of HMF to 2,5-tetrahydrofurandimethanol was the dominant route, and the acid-catalyzed routes became insignificant. The efficiency for hydrogenation of HMF was much higher in ethanol than in water. As for furfural, its hydrogenation proceeded more efficiently in the polar solvents (i.e. ethanol, diethyl ether)
Catalytic Transfer Hydrogenation of Furfural over CuNi@C Catalyst Prepared from Cu–Ni Metal-Organic Frameworks
作者:Feng Li、Shanshan Jiang、Yue Wang、Jin Huang、Cuiqin Li
DOI:10.1134/s0036024421010143
日期:2021.1
between Cu and Ni in the CuNi@C significantly enhanced the furfuraltransferhydrogenation activity and raised the furfural selectivity. The reaction conditions of furfuraltransferhydrogenation such as catalyst dosage, hydrogen donor, reaction temperature, and reaction time were studied. The catalytic mechanism for CTH of FF over CuNi@C catalyst was discussed.
The invention relates to the use of compounds of formula I
wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.